NEW YORK, October 6, 2016 /PRNewswire/ --
Stock-Callers.com is currently assessing the most recent performances ofthe following major players in the Drug Manufacturers segment: Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Retrophin Inc. (NASDAQ: RTRX), Heron Therapeutics Inc. (NASDAQ: HRTX), and GW Pharmaceuticals PLC (NASDAQ: GWPH). These companies belong
New York headquartered Tonix Pharmaceuticals Holding Corp.'s stock finished Wednesday's session 2.45% lower at $0.75 with a total trading volume of 732,177 shares. Shares of the Company, which engages in developing medicines for common disorders of the central nervous system, are trading below their 50-day moving average by 54.79%. The stock has a Relative Strength Index (RSI) of 27.24.
On September 6th, 2016, Tonix Pharmaceuticals announced preliminary topline results from its Phase 3 clinical study, AFFIRM, designed to evaluate the safety and efficacy of TNX-102 SL, 2.8 mg, in patients with fibromyalgia. The company stated that the AFFIRM data did not achieve statistical significance in the primary efficacy endpoint: the proportion of patients who reported a 30% or greater reduction in pain from baseline to the end of the 12-week treatment period based on the pre-specified primary analysis. However, TNX-102 SL did show statistically significant effects on pain when analyzed by other standard statistical approaches.
On September 7th, 2016, research firm ROTH Capital downgraded the Company's stock rating from 'Buy' to 'Neutral'. TNXP complete research report is just a click away at:
On Wednesday, shares in San Diego, California headquartered Retrophin Inc. ended the session at $23.12, up 1.49%. The stock recorded a trading volume of 338,299 shares. The Company's shares have gained 41.67% in the last one month, 26.34% in the previous three months, and 19.85% since the start of this year. The stock is trading 18.72% above its 50-day moving average and 35.83% above its 200-day moving average. Moreover, shares of Retrophin, which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, have an RSI of 62.41.
On September 30th, 2016, Retrophin announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management. Mr. Gagne's inducement award consists of a stock option to purchase 60,000 shares of Retrophin common stock. The stock option has an exercise price per share equal to the closing price of Retrophin's common stock on the date of grant. The complimentary report on RTRX can be downloaded at:
California headquartered Heron Therapeutics Inc.'s stock ended yesterday's session 6.90% higher at $17.20. A total volume of 1.14 million shares was traded, above their three months average volume of 719,630 shares. The Company's shares are trading 8.98% below their 50-day moving average. Additionally, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 42.48.
On September 6th, 2016, research firm Lake Street resumed its 'Buy' rating on the Company's stock, issuing a target price of $45 per share.
As per notes filed with the SEC, on September 30, 2016, Heron Therapeutics' board of directors accepted the resignations of Neil J. Clendeninn, M.D., Ph.D., its Senior Vice President, Chief Medical Officer, Paul G. Marshall, its Senior Vice President, Technical Operations, and Brian G. Drazba, its Vice President, Finance and Chief Financial Officer. Sign up for your complimentary report on HRTX at:
At the close on Wednesday, shares in Cambridge, the UK-based GW Pharmaceuticals PLC recorded a trading volume of 619,579 shares. The stock finished 0.23% higher at $133.45. The Company's shares have surged 58.49% in the last one month, 42.77% over the previous three months, and 92.18% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 36.42% and 69.70%, respectively. Furthermore, shares of GW Pharmaceuticals, which together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines, have an RSI of 80.45.
On September 26th, 2016, GW Pharmaceuticals announced positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added to the patient's current treatment, achieved the primary endpoint for both dose levels with high statistical significance.
On October 4th, 2016, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock, issuing a target price of $162 per share. Download the research report for free on GWPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...
Strabismus or squint is a failure of the two eyes to maintain proper alignment when looking at an ...View All